Stay updated on Pembrolizumab Combo in Resectable NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Resectable NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Resectable NSCLC Clinical Trial page
- Check5 days agoChange DetectedThe study page now shows a 403 Forbidden error, replacing the usual content and leaving a simple Home link. This means the record is temporarily inaccessible and trial details are not viewable on this page.SummaryDifference19%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedNIH funding entries for 2017 and 2023 were added to the page. The revision history now shows v3.6.6, and the previous v3.6.5 entry was removed.SummaryDifference0.1%

- Check40 days agoChange DetectedThe Plain Language Summary section was removed from the study record page, eliminating the patient-friendly overview of the trial and its purpose.SummaryDifference0.0%

- Check47 days agoChange Detected- The page revision has been updated to v3.6.5. The previous revision indicator v3.6.4 has been replaced.SummaryDifference0.0%

- Check54 days agoChange DetectedThe study record now includes new registry identifiers (UTN and EU CT) and adds data-sharing resources: a PDF with data-access procedures and an external data-sharing site, while older EngageZone links were removed. These changes place the trial's data-sharing framework and identifiers into current reference points for researchers and stakeholders.SummaryDifference0.1%

- Check61 days agoChange DetectedThe page's revision tag was updated from v3.6.3 to v3.6.4, indicating a new build of the underlying documentation/system. This change is an internal version update rather than a visible content update.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab Combo in Resectable NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Resectable NSCLC Clinical Trial page.